SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is sparking intense debate as traders weigh mounting institutional adoption and positive network milestones against persistent bearish technical patterns and market stagnation. The community remains sharply divided, with many actively accumulating at current levels while others warn of further downside risks if critical support levels fail to hold.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is experiencing significant volatility and trading momentum following an FDA advisory panel's positive recommendation to include BPC-157 on the list of approved compounding substances, a move the community views as a major expansion of the company's addressable market in the peptide sector. While some investors are bracing for a potential short squeeze given the high short interest, others remain cautious, debating whether this headline will translate into immediate revenue growth or if it represents a 'sell-the-news' event amidst broader market uncertainty.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is gaining momentum as investors weigh its pivot toward commercial efficiency and external innovation against persistent buyout speculation. The community is actively debating the impact of the research facility closure and leadership changes, while monitoring whether strong Orladeyo sales and high short interest will catalyze a significant trend reversal.

Tema ETF Trust - Tema Space Innovators ETF

Tema Space Innovators ETF

Tema Space Innovators ETF ($NASA) is experiencing significant downward pressure as its holdings, particularly those linked to SpaceX, face heavy selling and portfolio rebalancing amid concerns over lockup expiries and broader sector volatility. Investors remain divided, with some actively averaging down to capture long-term growth in the space economy, while others express frustration over the fund's inability to decouple from negative sentiment in the wider space sector.

Tidal Trust II - Defiance Daily Target 2x Long MSTR ETF

Defiance Daily Target 2x Long MSTR ETF

MSTX is experiencing significant volatility as investors closely monitor Bitcoin's price fluctuations and Michael Saylor's ongoing accumulation strategy. The community remains deeply divided, with many traders debating whether the stock's current price represents a strong entry point for a potential bounce or a dangerous trap due to the mechanics of leveraged decay.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc - Ordinary Shares - 144A

Nasdaq Inc

Nasdaq is facing intense community scrutiny and volatility following the implementation of stricter listing requirements and potential delisting rules, while broader market participants are actively debating whether recent tech sell-offs and macroeconomic pressures signal a structural bear trap or a necessary correction.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corporation is experiencing significant investor scrutiny following a negative CHMP opinion for YARTEMLEA in Europe, sparking concerns over commercial momentum and the company's regulatory path. The community is actively debating the impact of this European setback on U.S. market confidence while focusing on upcoming catalysts, such as the activation of the permanent J-code, expected NTAP reimbursement, and potential debt restructuring.

Oatly Group AB is a holding company, which focuses on developing expertise around oats, a global power crop with inherent properties suited for sustainability and human health. It operates through the following geographical segments: Europe & International, North America and Greater China. The company was founded by Björn Öste in 1994 and is headquartered in Malmö, Sweden.

Oatly Group AB - ADR

Oatly Group

Oatly is trending as investors focus on the upcoming earnings announcement and high-stakes negotiations surrounding a potential China strategic review, which are widely viewed as critical catalysts for the company's financial turnaround. The community is actively debating the company's path to profitability, its ability to expand shelf presence, and the long-term potential of its new product pipeline.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors react to China adding the company to its export control list, a move that reinforces its strategic importance as a U.S.-based, vertically integrated rare earth producer. The community is actively debating whether this geopolitical friction serves as a long-term bullish catalyst for domestic supply chain independence or creates short-term volatility, with many users highlighting recent insider buying and government support as key pillars of their conviction.

Tidal Trust II - YieldMax MSTR Option Income Strategy ETF

YieldMax MSTR Option Income Strategy ETF

MSTY is trending due to heightened community debate over its sustainability as investors weigh the impact of NAV erosion and reverse splits against its high-yield distribution model. While some proponents advocate for a 'hold and harvest' strategy to build long-term share counts, critics warn that the fund's mechanics create a structural downward spiral that makes recovery increasingly difficult as MicroStrategy's volatility fluctuates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

QuidelOrtho to Report Second Quarter 2026 Financial Results

QuidelOrtho to Report Second Quarter 2026 Financial Results QuidelOrtho to Report Second Quarter 2026 Financial Results PR Newswire SAN DIEGO, July 24, 2026 SAN DIEGO, July 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a leading global provider of...

Reasons to Add QuidelOrtho Stock in Your Portfolio for Now

QDEL's strong portfolio, cost-saving progress and mixed first-quarter results support growth, though respiratory reliance remains a risk.

DGX Stock Up on Q2 Earnings & Revenue Beat, '26 View Raised

Quest Diagnostics shares rise as second-quarter earnings and revenues beat estimates, testing demand surges and the company raises its 2026 outlook.

Beyond Fentanyl: How the Drug Crisis Is Changing

Beyond Fentanyl: How the Drug Crisis Is Changing Beyond Fentanyl: How the Drug Crisis Is Changing PR Newswire SAN DIEGO, July 23, 2026 SAN DIEGO, July 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 59 of its Science...

Kaskela Law Firm Announces Investigation of QuidelOrtho Corp. (QDEL) and Encourages Long-Term QDEL Shareholders with Investment Losses to Contact the Firm

Investor litigation firm Kaskela Law announces that it is investigating QuidelOrtho Corporation (Nasdaq: QDEL) (QuidelOrtho) on behalf of the companys long-term investors. Click here for additional information: https://kaskelalaw.com/case/quidelortho-corp/ Recently a securities fraud complaint was...

Zacks Industry Outlook Highlights Terumo, QuidelOrtho, Lumexa Imaging and Brainsway

Terumo stands out as medical products companies navigate cost pressures with innovation, pricing actions and demand for advanced diagnostics supporting growth.

4 Medical Products Stocks Poised to Win Despite Industry Headwinds

Terumo, QuidelOrtho, Lumexa Imaging and BrainsWay are tackling industry headwinds through innovation, pricing and execution as healthcare demand stays resilient.

QuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

QuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) QuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO, July 15, 2026 SAN DIEGO, July 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL)("QuidelOrtho"), a leading...

QuidelOrtho (QDEL) Moves 32.2% Higher: Will This Strength Last?

QuidelOrtho (QDEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

QDEL Stock Eyes Best Day In Over A Year — Point-Of-Care Sale Talks Ignite Rally

Equity

QuidelOrtho is in talks to sell its point-of-care testing unit behind the rapid antigen tests for Covid and flu, Financial Times reported over the weekend. 


QuidelOrtho Corp. operates as a vitro diagnostics company. It is focused on developing and manufacturing diagnostic products. The company was founded on May 27, 2022 and is headquartered in San Diego, CA.

QuidelOrtho Corporation

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards another losing week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

QDELQuidelortho Corp

Fundamentals

Latest QDEL News